When healthcare providers dismiss symptoms, it can cause lasting harm. A new study reveals how such invalidation affects ...

Clinical trial to evaluate the safety and efficacy of YK012 in primary membranous nephropathy- Globally, this is the first bispecific CD19-directed CD3 T cell engager immunotherapy for this autoimmune ...